



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The General Manager
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

The General Manager
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai - 400 001

IOLCP/CGC/2018
14 November 2018

Subject: Press Release with respect to Financial Results for the Quarter and half year ended 30 September 2018

Dear Sir,

Pursuant to Regulations 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release with respect to Financial Results for the Quarter and half year ended 30 September 2018. The same is also available on the website of the Company i.e. www.iolcp.com.

This is for your information & record please.

Thanking You

Yours faithfully
For IOL Chemicals and Pharmaceuticals Limited



(Krishna Singh)
Vice President and Company Secretary
ICSI membership no: A5584

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



For immediate release

Press Release

IOL Chemicals and Pharmaceuticals Ltd consistently reports robust performance in Q2' FY19

**Enhanced manufacturing facilities of Metformin (Unit IV)
from 3,000 TPA to 4,000 TPA
Completed Unit V to manufacture Clopidogrel Bisulphate and
Fenofibrate with capacity of 180 TPA**

Ludhiana. 14 November 2018: IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals posted robust performance consistently in the second quarter of financial year 2018-19.

Quarter on Quarter (QoQ) – September 2018 vis a vis June 2018

- Net Revenue from operations increased by 17% to ₹ 422.91 crore from ₹ 361.84 crore.
- EBIDTA increased to ₹ 80.89 crore from ₹ 43.43 crore showing increase of 86%.
- Net Profit increased by 166 % to ₹ 38.40 crore from ₹ 14.41 crore.

Year on Year (YoY) – September 2018 vis a vis September 2017

- Net Revenue from operations increased by 94% to ₹ 422.91 crore from ₹ 217.79 crore.
- EBIDTA increased to ₹ 80.89 crore from ₹ 30.02 crore showing increase of 169%.
- Net Profit increased by 767 % to ₹ 38.40 crore from ₹ 4.43 crore.

Half year ended 30 September 2018 vis a vis 30 September 2017

- Net Revenue from operations increased by 74% to ₹ 784.75 crore from ₹ 450.76 crore.
- EBIDTA increased to ₹ 124.32 crore from ₹ 57.64 crore showing increase of 116%.
- Net Profit increased by 613 % to ₹ 52.81 crore from ₹ 7.41 crore.

The company enhanced installed capacity of Metformin (Unit IV) from 3,000 TPA to 4,000 TPA with capex of ₹ 2.71 crore.



The Company has also successfully completed Unit V to manufacture Clopidogrel Bisulphate & Fenofibrate with a capacity of 180 TPA with capex of ₹ 19.26 crore. Both capex are funded through internal accruals.

Mr Vijay Garg, Joint Managing Director said "We are delighted to announce the enhancement of capacity of Metformin (Unit IV) from 3,000 TPA to 4,000 TPA due to increasing demand and successfully completed Unit V to manufacture Clopidogrel Bisulphate & Fenofibrate with a capacity of 180 TPA that will result in higher revenue and operating margins. Both capex are funded through internal accruals."

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and National Stock Exchange (Code: IOLCP) is one of the leading APIs/ bulk drugs Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 10,000 TPA and having backward integrated manufacturing facility at single location. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) was set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand, Iran etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

